Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Comparison | Adverse Events | NCT00615901 | NCT00829166 | the primary trial recorded many more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort. | Contradiction | [
0,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | {'Clinical Trial ID': 'NCT00615901', 'Intervention': ['INTERVENTION 1: ', ' Cohort A (CMF at 14 Day Intervals)', ' This is a pilot study using 8 cycles of CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2), at 14 day intervals supported by PEG-filgrastim for a cohort of 38 patients. A... | {'Clinical Trial ID': 'NCT00829166', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' Participants received trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.', ... | a70cc8e5-0ef5-4045-8fec-d9e7503b5e6e |
Comparison | Results | NCT00390455 | NCT00558103 | In both the secondary trial and the primary trial the test cohorts produced better results than the control groups. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT00390455', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Lapatinib)', ' Patients receive 1500 mg lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg)of each subsequent course.', 'INTERVENTION 2: ', ' Arm II (Placebo)... | {'Clinical Trial ID': 'NCT00558103', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo', ' Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD).', 'INTERVENTION 2: ', ' Cohort... | e852619c-312a-470f-8b77-149e79f69a3f |
Single | Adverse Events | NCT00003830 | The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected more than 10 patients in total. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00003830', 'Intervention': ['INTERVENTION 1: ', ' Arm I:Sentinel Node Resection+Conventional Axillary Dissection', ' Sentinel node resection immediately followed by axillary dissection', ' conventional surgery: Sentinel node resection immediately followed by axillary dissection.', 'INTERVEN... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 27160f45-e4cb-48be-8cf2-c23ced4578c0 | |
Comparison | Eligibility | NCT00754325 | NCT00399529 | the secondary trial and the primary trial both accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast. | Entailment | [
1,
2
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00754325', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant and Dasatinib', ' Arm 1: Participants in this group received a drug regimen that consisted of both fulvestrant and dasatinib.', ' Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day... | {'Clinical Trial ID': 'NCT00399529', 'Intervention': ['INTERVENTION 1: ', ' Allo GM-CSF-secreting Vaccine, Trastuzumab, Cyclophosphamide', ' Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part ... | e4b65e9f-10f6-4424-95d2-837e29587a63 |
Single | Eligibility | NCT01127373 | Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumors are eliglbe for the primary trial. | Contradiction | [
0,
5
] | [] | {'Clinical Trial ID': 'NCT01127373', 'Intervention': ['INTERVENTION 1: ', ' Radiation Therapy Via Multi-beam IMRT', ' This is a single-arm feasibility study of multi-beam IMRT with daily set-up verification in the treatment of women with node-positive breast cancer who will receive radiation to the breast/chest wall ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 68f6f3db-0bfb-4e03-8e2f-92ae5d0f55a1 | |
Single | Results | NCT01432886 | One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days. | Contradiction | [
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01432886', 'Intervention': ['INTERVENTION 1: ', ' E7389 With Weekly Trastuzumab', ' Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle. Trastuzumab was administered intravenously weekly, with an initial dose of 4 mg/kg followed by 2 mg/kg for the... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7796fe1b-1952-4339-90f3-47b051ebe927 | |
Comparison | Adverse Events | NCT01086605 | NCT00570921 | the primary trial and the secondary trial do not record any of the same adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT01086605', 'Intervention': ['INTERVENTION 1: ', ' Arm I/Group A (Pixantrone IV Day 1)', ' Patients receive 180 mg/m^2 pixantrone dimaleate IV over 1 hour on day 1. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.', 'INTERVEN... | {'Clinical Trial ID': 'NCT00570921', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant + Everolimus', ' Fulvestrant + Everolimus', ' Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day ... | c7df7b38-068b-48a8-b805-b8ebb3e854e6 |
Single | Eligibility | NCT00945061 | patients with Multi-focal breast cancer cannot be accepted for the primary trial. | Entailment | [
0,
3
] | [] | {'Clinical Trial ID': 'NCT00945061', 'Intervention': ['INTERVENTION 1: ', ' Intraoperative Radiation Therapy', ' Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.', 'INTERVENTION 2: ', ' Intracavitary Balloon Brachytherapy', ' Patients undergo partial... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 39227bbb-0e26-4ba0-94a7-762376541889 | |
Comparison | Intervention | NCT03283553 | NCT02679755 | the primary trial and the secondary trial have a different number of cohorts. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT03283553', 'Intervention': ['INTERVENTION 1: ', ' Multicomponent Intervention', " 1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss ... | {'Clinical Trial ID': 'NCT02679755', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib+Letrozole India Cohort', ' Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle. Participants received Letrozole orally at 2.5 mg once daily as continuous... | fdb7afc0-ef7e-44bf-bfe3-5252fa8b0106 |
Single | Eligibility | NCT02321527 | Patients with invasive breast cancer with a diameter of more than 70mm are included in the primary trial. | Contradiction | [
2
] | [] | {'Clinical Trial ID': 'NCT02321527', 'Intervention': ['INTERVENTION 1: ', ' CEUS Sentinel Lymph Node Imaging + Guided Biopsy', ' Subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension before Contrast-Enhanced Ultrasound (CEUS), sentinel lym... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fd15ddaf-1abc-4551-a5b3-08217b975e36 | |
Comparison | Results | NCT00054132 | NCT01421017 | As the primary trial and the secondary trial use very similar outcome metrics, we can easily compare and contrast across their results. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00054132', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Erlotinib Hydrochloride, Bevacizumab)', ' Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptabl... | {'Clinical Trial ID': 'NCT01421017', 'Intervention': ['INTERVENTION 1: ', ' IMQ+RT', ' This arm has been closed as of 6/4/2014.', ' Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)', ' Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied to all skin sites overnigh... | 067f4671-0720-4980-a0fa-8d01d31daa9a |
Comparison | Adverse Events | NCT02366130 | NCT01262027 | the primary trial reported more than 10 times the number of patients experiencing adverse events as the secondary trial . | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02366130', 'Intervention': ['INTERVENTION 1: ', ' Ra-223 Dichloride + Denosumab', ' Ra-223 dichloride 55 kBq/kg administered as a bolus intravenous (IV) injection (over 1 minute) through a secure in-dwelling catheter on day 1 of the study and then every four weeks thereafter for 6 cycles.', ... | {'Clinical Trial ID': 'NCT01262027', 'Intervention': ['INTERVENTION 1: ', ' Dovitinib', ' Dovitinib 500 mg single oral dose for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Patients have histological confirmati... | 026e7eb7-37fd-4aae-b74f-dacf905db262 |
Single | Eligibility | NCT02878057 | Patients that are fully active and able to carry on all pre-disease performance without restriction are excluded from the primary trial. | Contradiction | [
0,
5
] | [] | {'Clinical Trial ID': 'NCT02878057', 'Intervention': ['INTERVENTION 1: ', ' Advanced Breast Cancer', ' Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolera... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a79fc503-215f-40d4-9cc1-e101cec3a9c9 | |
Single | Results | NCT00191269 | the primary trial measured the Number of Participants With Disease Progression (PD) or Death, to evaluate the performance of its interventions. | Contradiction | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00191269', 'Intervention': ['INTERVENTION 1: ', ' Dose Level 1', ' Gemcitabine at 1000 mg/m2 administered intravenously over 30 to 60 minutes on Days 1 and 8 in each 3-week (21-day) cycle of study therapy.', 'INTERVENTION 2: ', ' Dose Level 2', ' Gemcitabine at 1250 mg/m2 administered intr... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ee5f95d0-3824-4ce4-bf58-1ecd3ce4e7ee | |
Comparison | Adverse Events | NCT00574587 | NCT00777049 | There were no cases of cardiac tamponade in the primary trial or the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT00574587', 'Intervention': ['INTERVENTION 1: ', ' Stratum A: VR-Paclitaxel-Trastuzumab', ' Stratum A: Vorinostat 200 (Dose Level 1) or 300 mg (Dose level 2) by mouth on days 1-3 plus weekly paclitaxel 80 mg x 12 weeks and trastuzumab 4 mg/kg, then 2 mg/kg x 12 weeks, followed by doxorubicin ... | {'Clinical Trial ID': 'NCT00777049', 'Intervention': ['INTERVENTION 1: ', ' ER+ and/or PgR+ (Arm I)', ' Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg', 'INTERVENTION 2: ', ' ER- and PgR- (Arm II)', ' Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg'], 'Eligibility': ['Inclusion Criteria:', ... | 7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a |
Comparison | Intervention | NCT03592121 | NCT01439711 | Unlike the secondary trial, the primary trial does not specify a specific dosage or frequency for its intervention. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT03592121', 'Intervention': ['INTERVENTION 1: ', ' AB-101', ' Apply to both nipple/areola regions approximately 1 hour prior to sexual activity', ' AB-101: Apply approximately 1 hour prior to sexual activity', 'INTERVENTION 2: ', ' Placebo', ' Apply to both nipple/areola regions approximat... | {'Clinical Trial ID': 'NCT01439711', 'Intervention': ['INTERVENTION 1: ', ' Letrozole + MRI', ' Protocol Therapy will consist of 6 months of letrozole, administered orally at a dose of 2.5 mg/day. Patients will have a bilateral MRI for disease evaluation at months 3 and 6.'], 'Eligibility': ['Eligibility Criteria:', ... | ccb703ea-df18-451b-8db8-ed0e510a4c0f |
Single | Adverse Events | NCT00284180 | Across both cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT00284180', 'Intervention': ['INTERVENTION 1: ', ' Vinflunine', ' Vinflunine 320 mg/m2 intravenously day 1 over 20 minutes repeated every 21 days', 'INTERVENTION 2: ', ' Vinflunine/Trastuzumab', ' Vinflunine 280 mg/m2 every 21 days with trastuzumab administered with a loading dose of 8 mg/k... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 56cd4492-3884-4b2a-a000-7c859d86f6f5 | |
Single | Adverse Events | NCT01492101 | less than 1% of either cohort of the primary trial was effect by either Pancytopenia or Coagulopathy. | Entailment | [
0,
4,
5,
11,
15,
16
] | [] | {'Clinical Trial ID': 'NCT01492101', 'Intervention': ['INTERVENTION 1: ', ' NKTR-102', ' NKTR-102: 145 mg/m2 NKTR-102 will be delivered q21day as a 90 minute intravenous (IV) infusion on day 1 of each treatment cycle.', 'INTERVENTION 2: ', " Physician's Treatment of Choice", " Treatment of Physician's Choice (TPC):... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 08b79e0d-5e97-45fb-ac83-0096b56f714b | |
Single | Results | NCT01466270 | The the primary trial placebo group had a over 10% higher mean retention than the donepezil hydrochloride PO QD group. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT01466270', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Patients receive donepezil hydrochloride PO QD.', ' donepezil hydrochloride: Given PO', 'INTERVENTION 2: ', ' Arm II', ' Patients receive placebo PO QD.', 'Placebo: Given PO'], 'Eligibility': ['INCLUSION CRITERIA:', ' Adults >18... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c524ecf2-1ca6-4a9a-bedf-f0709124fa1b | |
Comparison | Results | NCT00798135 | NCT01209195 | the primary trial and the secondary trial both investigate Pharmacokinetics Itraconazole 500mg QD. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00798135', 'Intervention': ['INTERVENTION 1: ', ' Itraconazole', ' oral itraconazole 200mg a day until disease progression or unacceptable toxicities.'], 'Eligibility': ['Inclusion Criteria:', ' - Patients must have a pathologically confirmed diagnosis of invasive carcinoma of the breast. -... | {'Clinical Trial ID': 'NCT01209195', 'Intervention': ['INTERVENTION 1: ', ' Part 1: Dose Escalation: Cohort 1', ' MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV', 'INTERVENTION 2: ', ' Part 1: Dose Escalation: Cohort 2', ' MM-121 - 40 mg/kg loading dose followed by 20 m... | 6d549a9b-47bf-4369-962b-2759cfd7051e |
Comparison | Eligibility | NCT00703326 | NCT00274768 | Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial. | Entailment | [
0,
3,
5
] | [
0,
1,
7,
8
] | {'Clinical Trial ID': 'NCT00703326', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab (IMC-1121B) + Docetaxel', ' Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.', ' Docetaxel is administered at a dose of 75 mil... | {'Clinical Trial ID': 'NCT00274768', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine', ' The starting dose of capecitabine was 3,000 mg (total daily dose) given in two divided daily doses for 14 days followed by 7 days of rest (1 cycle = 21 days). Missed doses were not substituted. Treatment was continued until u... | 596f20cf-299d-40a3-881a-cdd49bcb21f6 |
Single | Adverse Events | NCT03066947 | At least one patient in the primary trial suffered from Gastroesophageal reflux disease. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT03066947', 'Intervention': ['INTERVENTION 1: ', ' SV-BR-1-GM Monotherapy', ' Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alph... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 78ae19aa-6e26-4f9a-b381-cd77d92e4ecb | |
Comparison | Eligibility | NCT00418028 | NCT00293540 | Sam has recently received a liver transplant, he is not eligible for the primary trial, but is eligible for the secondary trial. | Entailment | [
7,
10
] | [
0,
1,
2,
3,
4
] | {'Clinical Trial ID': 'NCT00418028', 'Intervention': ['INTERVENTION 1: ', ' Arm A (Cint)', ' Capecitabine will be administered orally at a dose of 1250 mg/m2 twice-daily (in the morning and in the evening, the equivalent of a total daily dose of 2500 mg/m2) for 14 days, in 3 week cycles with a resting period of 7 day... | {'Clinical Trial ID': 'NCT00293540', 'Intervention': ['INTERVENTION 1: ', ' A Mid-luteal Surgery', '[Not Specified]', 'INTERVENTION 2: ', ' B Mid-follicular Surgery', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Estrogen receptor or progesterone receptor positive breast cancer', ' Premenopausal with... | 1d4f9f95-6f97-4054-9dd8-fe78aa5fc685 |
Single | Intervention | NCT01781299 | all subjects in the primary trial must undergo a minor surgery. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT01781299', 'Intervention': ['INTERVENTION 1: ', ' AlloDerm RTU', ' Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.', 'AlloDerm RTU', 'INTERVENTION 2: ', ' SurgiMend PRS', ' Participants within this arm will... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d4b2d877-34af-4944-84f7-046e22c2854e | |
Single | Results | NCT00119262 | cohorts 1 and 2 of the primary trial recorded a different number of patients that suffered from Congestive Heart Failure. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00119262', 'Intervention': ['INTERVENTION 1: ', ' Arm A (ddBAC > BT > B)', ' Dose dense bevacizumab, cyclophosphamide and doxorubicin, followed by paclitaxel and bevacizumab, followed by bevacizumab', 'INTERVENTION 2: ', ' Arm B (ddAC > BT > B)', ' Dose dense doxorubicin and cyclophosphami... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d3ca3729-2795-4cd5-9968-666781d17fac | |
Single | Adverse Events | NCT01752907 | There were 0 observed cases of Tibia or Fibula fractures in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT01752907', 'Intervention': ['INTERVENTION 1: ', ' General Education DVD', ' Participants received chemotherapy and pegfilgrastim administered as a single subcutaneous injection dose of 6 mg 24 to 72 hours after chemotherapy. Participants were required to watch a general chemotherapy side eff... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fb85a3a5-b9a1-48f4-84f3-2e2307e2f104 | |
Comparison | Adverse Events | NCT01901146 | NCT00209092 | Cohort 1 of the primary trial recorded the same number of instances of Neutropenic fever as Cohort 1 of the secondary trial. | Contradiction | [
0,
2
] | [
0,
4
] | {'Clinical Trial ID': 'NCT01901146', 'Intervention': ['INTERVENTION 1: ', ' ABP 980', ' Participants received ABP 980 at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.', 'INTERVENTI... | {'Clinical Trial ID': 'NCT00209092', 'Intervention': ['INTERVENTION 1: ', ' Arm A:Sequential Therapy', ' Docetaxel will be given at 100mg/m^2 intravenously Day1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth D1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).', 'I... | b98c7a50-ed79-41ff-9733-fff143f630be |
Comparison | Intervention | NCT02203565 | NCT00194779 | laboratory biomarker analysis is used in the secondary trial and the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | {'Clinical Trial ID': 'NCT02203565', 'Intervention': ['INTERVENTION 1: ', " Supportive Care (Dakin's Solution, Radiation Therapy)", " Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks.", " Dakin's solution: Applied topically", ' radiation therap... | {'Clinical Trial ID': 'NCT00194779', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Neoadjuvant Therapy, Adjuvant Therapy)', ' See Detailed Description.', ' doxorubicin hydrochloride: Given IV', ' cyclophosphamide: Given PO', ' paclitaxel: Given IV', ' filgrastim: Given SC', ' capecitabine: Given PO', ' meth... | 47aa5686-75af-4ed8-b4ff-715b458ce40a |
Comparison | Intervention | NCT00077376 | NCT01256008 | the primary trial investigates a novel chemotherapy treatment, whereas the secondary trial is testing a type of psychological therapy. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00077376', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab/Ixabepilone/Carboplatin', ' During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cyc... | {'Clinical Trial ID': 'NCT01256008', 'Intervention': ['INTERVENTION 1: ', ' Stage 1 Clinical Management', ' The group will receive clinical management treatment only each session.', ' Clinical Management: Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview an... | e89fdc93-d624-4ba7-aa64-574a278e982b |
Single | Adverse Events | NCT00871858 | 1 patient in cohort 1 of the primary trial was diagnosed with a Clear cell renal cell carcinoma. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00871858', 'Intervention': ['INTERVENTION 1: ', ' Arm A (ANA)', ' Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.', ' anastrozole: Given orally', 'INTERVENTION 2: ', ' Arm B (FULV)', ' Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solut... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1739541a-2d3f-4a13-b956-769a1cbed4d7 | |
Single | Adverse Events | NCT02187744 | One patient in the primary trial suffered from sepsis, due to the presence of an implanted device. | Entailment | [
0,
7
] | [] | {'Clinical Trial ID': 'NCT02187744', 'Intervention': ['INTERVENTION 1: ', ' PF-05280014', ' Participants received a loading dose of 8 mg/kg of PF-05280014 on Cycle 1 Day 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg. Taxotere 75 mg/m2 and carboplatin AUC 6 were administered on Day 1 of each cy... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c8f401a0-5e7d-4fd9-b31e-0866c9bee6a9 | |
Single | Intervention | NCT02312622 | Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days , the differences between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC and the num... | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT02312622', 'Intervention': ['INTERVENTION 1: ', ' Cohort A - Pegylated Irinotecan to Treat NSCLC', ' Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable tox... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 206fc00c-2c34-42bc-8fca-44be696e03c9 | |
Single | Results | NCT00393939 | Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00393939', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel + Sunitinib', ' Sunitinib 37.5 milligrams (mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2) every 3 weeks, or sunitinib 37.5 mg dai... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d | |
Single | Eligibility | NCT00581256 | Patients with left-sided breast cancer and an ECOG between 1-2 are excluded from the primary trial. | Contradiction | [
0,
4,
8,
14,
17
] | [] | {'Clinical Trial ID': 'NCT00581256', 'Intervention': ['INTERVENTION 1: ', ' IMRT', ' Best Delivery-optimized radiotherapy technique (IMRT)', ' IMRT: All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 83cef795-d4a8-486c-8ac1-34a9acee9672 | |
Comparison | Adverse Events | NCT00127933 | NCT00191789 | the primary trial recorded one patient with a catheter-related complication, whereas in the secondary trial none where observed. | Entailment | [
12,
25
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | {'Clinical Trial ID': 'NCT00127933', 'Intervention': ['INTERVENTION 1: ', ' HER2-Neu Negative', ' Dose and route per treatment cycle (Q3W):', ' Capecitabine: 825 mg/m2, orally, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1', ' HER2-neu negative: capecitabine + docetaxel', ' Duration: Four 3-week t... | {'Clinical Trial ID': 'NCT00191789', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine+Doxorubicin+Cisplatin+Surgery', ' Gemcitabine: 1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8).', ' Doxorubicin: 60 mg/m^2, IV, eve... | b3cee7a6-cec1-4676-974d-7cfb3ccd9919 |
Comparison | Eligibility | NCT00944047 | NCT00228943 | Patients with HER2 positive tumors are excluded from the primary trial, but may be included in the secondary trial. | Contradiction | [
0,
4
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00944047', 'Intervention': ['INTERVENTION 1: ', ' Intervention Arm', ' Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery', ' nab-paclitaxel: 100 MG/M2 IV over 30 minutes once a week for 12 weeks', ' trastuzumab: 4 MG loading dose followed by 2 MG/KG... | {'Clinical Trial ID': 'NCT00228943', 'Intervention': ['INTERVENTION 1: ', ' Full Strength Acute Tryptophan Depletion', '[Not Specified]', 'INTERVENTION 2: ', ' Half-Strength Tryptophan Depletion - Control', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' At least 18 years of age', ' Willing and able to... | 007de11b-4265-4695-b18e-e0d6909a347a |
Comparison | Intervention | NCT01869764 | NCT02556632 | Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis and completes a Questionnaire. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT01869764', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Omega-3 Fatty Acid)', ' Patients receive omega-3 fatty acid PO daily for 7-14 days.', 'omega-3 fatty acid: Given PO', ' laboratory biomarker analysis: Correlative studies', 'INTERVENTION 2: ', ' Arm II (Placebo)', ' Patients receive... | {'Clinical Trial ID': 'NCT02556632', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Curcumin-based Gel)', ' Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.', 'Curcumin-based ... | ce621235-b584-439b-bb11-ab2fa04c3195 |
Comparison | Intervention | NCT01646346 | NCT03283553 | the secondary trial and the primary trial both use irradiation techniques in their studies. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01646346', 'Intervention': ['INTERVENTION 1: ', ' 4D Conformal Image-Guided Partial Breast RT', ' This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days.', ' 4D Conformal Image-Guided Partial Breast RT: External bea... | {'Clinical Trial ID': 'NCT03283553', 'Intervention': ['INTERVENTION 1: ', ' Multicomponent Intervention', " 1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss ... | f358f023-2393-44eb-9535-3f0e1851318d |
Single | Intervention | NCT00470301 | Every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00470301', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' See Detailed Description', ' tipifarnib: Given orally', ' paclitaxel: Given IV', ' doxorubicin hydrochloride: Given IV', ' cyclophosphamide: Given IV', ' pegfilgrastim: Given SC', ' conventional surgery: surgical procedures pe... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0e963b25-0d2b-4fc6-89c6-1eb068bc092e | |
Single | Results | NCT00733408 | There was just under 8 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00733408', 'Intervention': ['INTERVENTION 1: ', ' Tx (Chemo, MoAb, and Enzyme Inhibitor)', ' INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 d... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 390b08d3-e147-47f9-82d7-0643b8d5c8ae | |
Comparison | Intervention | NCT00994279 | NCT00545077 | Between both the primary trial and the secondary trial Bevacizumab is only administered to patients in cohort 2 of the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00994279', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Yoga Intervention', ' Yoga Intervention', ' Yoga: Yoga sessions', 'INTERVENTION 2: ', ' Arm 2: Educational Wellness Group', ' Educational Wellness Group', ' Education: Educational Wellness Group'], 'Eligibility': ['Inclusion Criter... | {'Clinical Trial ID': 'NCT00545077', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Endocrine Therapy (ET)', ' Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. T... | 2570cb04-4edd-48c9-b634-9f2e086469de |
Single | Results | NCT00270894 | 60 patients in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00270894', 'Intervention': ['INTERVENTION 1: ', ' Neoadjuvant Therapy', ' Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuz... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f6a7e279-b923-45e3-8ad5-e81e17c0a682 | |
Comparison | Eligibility | NCT02511730 | NCT00193206 | Patients with prior chemotherapy are eligible for the primary trial, but excluded from the secondary trial. | Entailment | [
0,
1,
2,
3
] | [
0,
6
] | {'Clinical Trial ID': 'NCT02511730', 'Intervention': ['INTERVENTION 1: ', ' FFDM Plus DBT', ' Breast Images with FFDM and DBT', ' FFDM Plus DBT: Fujifilm Aspire Cristalle System', 'INTERVENTION 2: ', ' FFDM', ' Breast Images with FFDM alone', ' FFDM: Fujifilm Aspire Cristalle System'], 'Eligibility': ['Inclusion ... | {'Clinical Trial ID': 'NCT00193206', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' Systemic Therapy', ' ABI-007 : ABI-007 175 mg/m2 D1 q 14 days x 6 cycles', ' Epirubicin : Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles', ' Gemcitabine : Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles'], 'Eligibility': ['... | 3d82851c-f302-4988-bd78-232583e04e96 |
Single | Intervention | NCT01819233 | All the primary trial participants have the same number of calories in their diets throughout the duration of the study. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT01819233', 'Intervention': ['INTERVENTION 1: ', ' Behavioral Dietary Intervention', ' Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric inta... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5c9f5916-37d3-4f6f-977b-be70204cf57c | |
Comparison | Intervention | NCT01156987 | NCT02234479 | Participants in the primary trial are assigned an intervention depending on their cancer diagnosis, whereas in the secondary trial the interventions are randomly assigned. | Entailment | [
0,
1,
2,
3,
13,
14,
15,
16
] | [
0,
1,
2,
5,
6,
7
] | {'Clinical Trial ID': 'NCT01156987', 'Intervention': ['INTERVENTION 1: ', ' Healthy Volunteers', ' Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.', ' Magnetic resonance imaging: Patients and healthy volunteers will be... | {'Clinical Trial ID': 'NCT02234479', 'Intervention': ['INTERVENTION 1: ', ' Hydrophor (Group A)', ' Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing ... | 0c5f2498-4c10-4e51-8915-d86b37b08156 |
Single | Adverse Events | NCT00545688 | There were no patients with paranasal sinus reactions, or Left ventricular dysfunction in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [] | {'Clinical Trial ID': 'NCT00545688', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab+Docetaxel', ' Neoadjuvant (Pre-Operative) Treatment: Participants received trastuzumab IV infusion at a loading dose of 8 mg/kg on Day 1 of Cycle 1 (21-day cycle) followed by a maintenance dose of 6 mg/kg on Day 1 of Cycles 2-4 an... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c54dc963-671a-4384-8b1f-d8058a832131 | |
Single | Adverse Events | NCT02340221 | A total of 32 patients in the primary trial had Diarrhoea. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT02340221', 'Intervention': ['INTERVENTION 1: ', ' Placebo+Fulvestrant', ' Participants received placebo taken orally QD beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4 | |
Single | Adverse Events | NCT00014222 | Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded none. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00014222', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: CEF', ' 6 cycles - q 28 days (6 months) - Cyclophosphamide 75 mg/m2 - po - Days 1-14 - Epirubicin 60 mg/m2 - IV - Days 1 and 8 - 5 Fluorouracil: 500mg/m2 - IV - Days 1 and 8 + Continuous Antibiotic Prophylaxis with Cotrimoxazole 960 mg... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 91adb350-ab20-41a6-944d-c13b55cf33f2 | |
Comparison | Results | NCT02038010 | NCT00764322 | Neither the primary trial or the secondary trial are measuring Dose Limiting Toxicity of BYL719 in Combination With T-DM1. | Contradiction | [
0,
1,
2,
3,
4
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02038010', 'Intervention': ['INTERVENTION 1: ', ' Cohort -1 (250mg BYL719, 3.6mg/kg T-DM1)', ' Patients receive 250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat every 21 days in the absence of dis... | {'Clinical Trial ID': 'NCT00764322', 'Intervention': ['INTERVENTION 1: ', ' Ultra-rapid Metabolizers', ' Those with the highest transformation of the CYP2D6 genotype to allelic activity', 'INTERVENTION 2: ', ' Extensive Metabolizers', ' Those with the most normal transformation of the CYP2D6 genotype to allelic act... | 78949f1f-6738-4220-a233-e7831902e6f3 |
Comparison | Results | NCT00390455 | NCT00558103 | In both the secondary trial and the primary trial the test cohorts achieved better overall response than the control groups. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT00390455', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Lapatinib)', ' Patients receive 1500 mg lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg)of each subsequent course.', 'INTERVENTION 2: ', ' Arm II (Placebo)... | {'Clinical Trial ID': 'NCT00558103', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo', ' Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD).', 'INTERVENTION 2: ', ' Cohort... | 135311d8-c579-4568-913e-937be00dde7e |
Comparison | Intervention | NCT00258349 | NCT01328249 | Cohort 1 of the primary trial does not receive any Eribulin Mesylate With Prophylactic Filgrastim, whereas both cohorts in the secondary trial receive some. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00258349', 'Intervention': ['INTERVENTION 1: ', ' Vorinostat +Trastuzumab', ' Trastuzumab: 6 mg/kg once on Day 1, infused over 90 minutes, every 3 weeks;', ' Vorinostat 200 mg of SAHA orally twice a day, daily for 14 days out of a 21-day cycle'], 'Eligibility': ['Inclusion Criteria:', ' No... | {'Clinical Trial ID': 'NCT01328249', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Eribulin Mesylate With Filgrastim as Needed', " Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles. Eribulin mesylate was admini... | 0984431d-4997-41dc-9ba4-07134568c3fa |
Single | Eligibility | NCT00662129 | Patients with Platelet count over 100,000/mm³, ANC < 1,700/mm³ and Hemoglobin between 11 to 18 grams per deciliter are eligible for the primary trial. | Entailment | [
18,
22,
23,
24
] | [] | {'Clinical Trial ID': 'NCT00662129', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel + Gemcitabine + Bevacizumab', ' Patients receive 125 mg/m^2 paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and 1000 mg/m^2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and 15 mg/kg bevaci... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d9dc4a6d-a913-46ac-b0aa-d50823ff2305 | |
Comparison | Results | NCT02435680 | NCT01743560 | the secondary trial and the primary trial use non comparable evaluation metrics, and significantly different time frames. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02435680', 'Intervention': ['INTERVENTION 1: ', ' All MCS110+Carboplatin+Gemcitabine', ' experimental. all MCS110 treated patients, with 10mg/kg intravenous infusion, on day 1 and days 1 & 8', 'INTERVENTION 2: ', ' Carboplatin+Gemcitabine', ' comparator. Gemcitabine: Intravenous infusion 1... | {'Clinical Trial ID': 'NCT01743560', 'Intervention': ['INTERVENTION 1: ', ' Everolimus and Exemestane', ' Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o. and exemestane 25mg daily p.o.'], 'Eligibility': [... | 9d9ab190-cdcf-4320-b69a-12f2dad9dba9 |
Comparison | Intervention | NCT01385137 | NCT00593346 | Placebo treatment is used in cohort 2 of the secondary trial, but there is only a test group in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01385137', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Omega-3-fatty Acid)', ' Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Arm II (Placebo)', ' Pa... | {'Clinical Trial ID': 'NCT00593346', 'Intervention': ['INTERVENTION 1: ', ' Accelerated Partial Breast Brachytherapy', ' Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.', ' Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given o... | 89fdf182-7474-4e70-baf7-03c8920c4ff3 |
Single | Results | NCT00422903 | Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00422903', 'Intervention': ['INTERVENTION 1: ', ' Letrozole + Placebo', ' Letrozole tablets in the dose of 2.5 milligrams (mg) plus matching placebo were administered orally once daily for 6 months prior to surgery.', 'INTERVENTION 2: ', ' Letrozole + Lapatinib', ' Letrozole tablets in the... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9f2fd0cc-af87-433d-9d2f-6235591d6cb1 | |
Comparison | Intervention | NCT02413008 | NCT02725801 | The interventions in the primary trial and the secondary trial are applied daily for a period of several months. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02413008', 'Intervention': ['INTERVENTION 1: ', ' 0.005% Estriol Vaginal Gel', ' Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly admini... | {'Clinical Trial ID': 'NCT02725801', 'Intervention': ['INTERVENTION 1: ', ' One-port', ' intervention is placement of one-port tissue expander at time of reconstruction', ' Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruc... | 90364098-7e9a-47be-ab2e-f66958cfb09d |
Comparison | Intervention | NCT00331552 | NCT01306942 | The same dose of trastuzumab was used for the interventions in the primary trial and the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00331552', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Cyclophosphamide, Doxil, Trastuzumab', ' Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease p... | {'Clinical Trial ID': 'NCT01306942', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2', ' Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg... | 021c3f62-8067-49e3-9d4b-c7641feb2548 |
Single | Eligibility | NCT01702571 | Patients with incurable and unresectable Breast Cancer are eligible for the primary trial, unless it is metastatic. | Contradiction | [
0,
4
] | [] | {'Clinical Trial ID': 'NCT01702571', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine (All Participants)', ' This cohort (Cohort 1) enrolled all participants with HER2 positive, unresectable, LABC or mBC who had received prior anti-HER2 and chemotherapy treatment and had progressed on or after the most re... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6893c9b4-d3a3-47a8-ada9-8aef67de2375 | |
Single | Eligibility | NCT00859651 | Helen had stage III ovarian cancer 2 years prior, from which she is still recovering, she is excluded from the primary trial. | Entailment | [
13,
14
] | [] | {'Clinical Trial ID': 'NCT00859651', 'Intervention': ['INTERVENTION 1: ', ' Cholecalciferol 20,000 IU Group', ' Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.', 'INTERVENTION 2: ', ' Cholecalciferol 30,000 IU Gro... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b88cde11-ae29-48e8-832b-4b9cb2596c30 | |
Comparison | Results | NCT02472964 | NCT00089661 | the primary trial studies changes in tumour diameter, whereas the secondary trial investigates changes in heart failure rate. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02472964', 'Intervention': ['INTERVENTION 1: ', ' Herceptin© + Taxane', ' Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint... | {'Clinical Trial ID': 'NCT00089661', 'Intervention': ['INTERVENTION 1: ', ' Denosumab 60 mg Q6M', '[Not Specified]', 'INTERVENTION 2: ', ' Placebo', '[Not Specified]'], 'Eligibility': ['Histologically or cytologically confirmed adenocarcinoma of the breast', ' Subjects with early stage disease who are estrogen recep... | ebe7078c-fd8b-439a-b1f5-7bd482071ead |
Single | Intervention | NCT02312622 | Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle), the difference between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT02312622', 'Intervention': ['INTERVENTION 1: ', ' Cohort A - Pegylated Irinotecan to Treat NSCLC', ' Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable tox... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d0b9c11c-50f2-4803-a96c-fff3ca90cf36 | |
Comparison | Intervention | NCT01256008 | NCT00300781 | the primary trial is investigating Cognitive behavioural therapy, a type of psychotherapy, in contrast the secondary trial studies Trastuzumab, a type of chemotherapy. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01256008', 'Intervention': ['INTERVENTION 1: ', ' Stage 1 Clinical Management', ' The group will receive clinical management treatment only each session.', ' Clinical Management: Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview an... | {'Clinical Trial ID': 'NCT00300781', 'Intervention': ['INTERVENTION 1: ', ' Neratinib 240, Prior Trastuzumab', ' Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily, as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment.', 'INTERV... | b620e1c5-69c4-4c30-9006-faa346200b60 |
Single | Results | NCT00325598 | There is no difference in results or cohort size between cohort 1 and 2 of the primary trial, the increase in Gy has no notable effect. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00325598', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1 (36 Gy)', ' 36 Gy in 9 fractions BID x 4 1/2 treatment days', ' Partial Breast Irradiation (PBI)', 'INTERVENTION 2: ', ' Cohort 2 (40 Gy)', ' 40 Gy in 10 fractions BID over 5 treatment days', ' Partial Breast Irradiation (PBI)'],... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0900325b-6ecd-46f1-b3f1-a2ce1605d151 | |
Comparison | Eligibility | NCT02419807 | NCT00777101 | Patients with HER2 + breast cancer are eligible for both the primary trial and the secondary trial. However, only patients with stage 1-2 breast cancer are eligible for the primary trial, and patients with stage 3-4 are eligilbe for the secondary trial. | Entailment | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT02419807', 'Intervention': ['INTERVENTION 1: ', ' Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer)', ' Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyani... | {'Clinical Trial ID': 'NCT00777101', 'Intervention': ['INTERVENTION 1: ', ' Neratinib', ' Neratinib', ' Neratinib: Tablets, 240mg once per day until disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Lapatinib+Capecitabine', ' Lapatinib plus Capecitabine', ' Lapatinib: Tablets 1250mg once per da... | 6f10e1f3-1197-464e-b574-d697fb49331d |
Comparison | Intervention | NCT03592121 | NCT01439711 | the secondary trial and the primary trial both require their patients to receive their respective interventions on a daily basis. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT03592121', 'Intervention': ['INTERVENTION 1: ', ' AB-101', ' Apply to both nipple/areola regions approximately 1 hour prior to sexual activity', ' AB-101: Apply approximately 1 hour prior to sexual activity', 'INTERVENTION 2: ', ' Placebo', ' Apply to both nipple/areola regions approximat... | {'Clinical Trial ID': 'NCT01439711', 'Intervention': ['INTERVENTION 1: ', ' Letrozole + MRI', ' Protocol Therapy will consist of 6 months of letrozole, administered orally at a dose of 2.5 mg/day. Patients will have a bilateral MRI for disease evaluation at months 3 and 6.'], 'Eligibility': ['Eligibility Criteria:', ... | cbf91beb-829b-488f-8e80-3b08b891a181 |
Single | Eligibility | NCT00254592 | Patients needing active supportive care can participate in the primary trial. | Contradiction | [
0,
9
] | [] | {'Clinical Trial ID': 'NCT00254592', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy With GM-CSF', ' Doxorubicin and Cyclophosphamide (AC) with Granulocyte-macrophage colony-stimulating factor (GM-CSF) (days 4-13) Followed by Weekly Carboplatin/Nab- Paclitaxel'], 'Eligibility': ['Inclusion Criteria:', ' Patients... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 985df98b-b397-4dbc-8fad-43ada30927d7 | |
Comparison | Intervention | NCT00356811 | NCT00296036 | The the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication on the skin of the hands or feet, but rather onto the breast or chest wall. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00356811', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib Plus Paclitaxel', ' Participants received lapatinib 1500 mg orally OD with paclitaxel, administered as a 1-hour IV infusion at a dose of 80 mg/m^2 on Days 1, 8, and 15 (±2 days) of a 28-day treatment cycle for at least 6 months. Par... | {'Clinical Trial ID': 'NCT00296036', 'Intervention': ['INTERVENTION 1: ', ' Urea/Lactic Acid Cream', ' Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily.', 'INTERVENTION 2: ', ' Placebo Cream', ' Patients receive placebo cream applied to palms and soles twice daily.'], 'El... | 0d4fdeef-89b2-463b-8252-66fa51d9ce8c |
Single | Results | NCT02595372 | 27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with Minocycline Hydrochloride did not have Pathological Complete Response. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT02595372', 'Intervention': ['INTERVENTION 1: ', ' High Dose Omeprazole Treatment', ' Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery.'], 'Eligibility': ['Inclusion Criteria', ' Newly diagnosed triple negative br... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2c270b8f-d1a4-4686-a75c-bb3ac4b0c6fe | |
Single | Results | NCT00450866 | In the primary trial group A has a higher percentage of patients with >25% increase in tumor area at 3 months after treatment than group B. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT00450866', 'Intervention': ['INTERVENTION 1: ', ' Epothilone B: Group A', ' Group A: Patients with progressive, radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT). Patupilone will be administered as a single intravenous infusion over 20 minute... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 494c1f01-5a2d-409e-b614-5871f408fbe6 | |
Comparison | Adverse Events | NCT01008150 | NCT00375427 | In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT01008150', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Paclitaxel + Trastuzumab Then A C', ' 4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Followin... | {'Clinical Trial ID': 'NCT00375427', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid Every 3 Months', ' Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 ... | 17881072-2517-483f-9c03-1edad21a58cf |
Single | Eligibility | NCT00093795 | Patients with cancer cells that have metastasised into less than 3 lymph nodes, with at least one larger than 2mm, cannot enter the primary trial. | Contradiction | [
0,
8
] | [] | {'Clinical Trial ID': 'NCT00093795', 'Intervention': ['INTERVENTION 1: ', ' Group 1: TAC X 6', ' Doxorubicin, cyclophosphamide, and docetaxel.', ' Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles', ' Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles', '... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 58ba5dfd-3d8d-42e4-8cff-3c179fcd43a7 | |
Single | Adverse Events | NCT00912340 | Less patients in cohort 2 of the primary trial had an unusual amount of fluid around the lungs than in cohort 1. | Contradiction | [
0,
7,
8,
15
] | [] | {'Clinical Trial ID': 'NCT00912340', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Patients receive trastuzumab IV over 30 minutes once every 3 weeks and continue to receive their most recent hormone therapy. Patients achieving disease progression receive everolimus PO daily in combination with trastuzumab a... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | da6ce3a9-b653-47b2-9271-f831e4de3f19 | |
Single | Adverse Events | NCT00828074 | A higher number of cohort 2 participants from the primary trial experienced fever, compared to cohort 1. | Contradiction | [
0,
5,
13,
18
] | [] | {'Clinical Trial ID': 'NCT00828074', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dose Level 1 - Vinorelbine at 20mg/m^2', ' Vinorelbine at 20mg/m^2 weekly intravenous (I.V.) on days 1, 8, 15 and sorafenib 200 mg given orally (p.o.) twice daily for 28 days', 'INTERVENTION 2: ', ' Phase I: Dose Level 2 - Vinorelbi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 66979ae5-a709-4adf-9067-287f0f92b9e2 | |
Single | Eligibility | NCT02692755 | Only Black women are eligible for the primary trial, as long as they do not have uncontrolled or symptomatic brain metastases. | Entailment | [
0,
1,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT02692755', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib + Letrozole or Fulvestrant', ' Palbociclib + Letrozole or Fulvestrant: Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until prog... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0af6799b-655f-4b8b-a192-ce8dcbb2fcff | |
Single | Eligibility | NCT00072293 | Patients with a palpable breast lesions and axillary lymph nodes are eligible for the primary trial. | Contradiction | [
3,
12
] | [] | {'Clinical Trial ID': 'NCT00072293', 'Intervention': ['INTERVENTION 1: ', ' Axillary Dissection', ' Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.', ' Axillary lymph node dissection: Axillary lymph node dissection', 'INTERVENTION... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3a3e2387-c4c7-48e6-b3ca-1257de7019c2 | |
Comparison | Intervention | NCT00537771 | NCT00354640 | participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole PO QD. | Entailment | [
0,
1,
2
] | [
0,
5
] | {'Clinical Trial ID': 'NCT00537771', 'Intervention': ['INTERVENTION 1: ', ' Arimidex Group', ' Anastrozole(ARIMIDEX): 1 mg once daily oral dose', 'INTERVENTION 2: ', ' TAM Group', ' Tamoxifen : 20 mg once daily oral dose'], 'Eligibility': ['Inclusion Criteria:', ' Histologically proven HR+ invasive breast cancer',... | {'Clinical Trial ID': 'NCT00354640', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole and Simvastatin', ' adjuvant therapy : laboratory analysis', ' pharmacological study : laboratory analysis', ' simvastatin : 40 milligram tablet PO QD for 14 days', ' anastrozole : 1 milligram tablet PO QD for 14 days'], 'Eligi... | 46ac8a9f-77ab-40cf-9421-64aad4ae6976 |
Comparison | Results | NCT00445458 | NCT00950742 | the primary trial and the secondary trial measure the DLT of their respective interventions, using the same time frame. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00445458', 'Intervention': ['INTERVENTION 1: ', ' Neratinib 160 mg + Paclitaxel 80 mg/m²', ' Neratinib 160 mg qd + Paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle.', 'INTERVENTION 2: ', ' Neratinib 240 mg + Paclitaxel 80 mg/m²', ' Neratinib 240 mg qd + Paclitaxel 80 mg/m² IV ... | {'Clinical Trial ID': 'NCT00950742', 'Intervention': ['INTERVENTION 1: ', ' Afatinib 20mg + Herceptin', ' Patients received continuous daily dosing with Afatinib 20mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit. This group includes pat... | d2b7253b-0654-4bb1-a9a4-b203714d64f9 |
Comparison | Adverse Events | NCT00107276 | NCT00232505 | Less than 5% of patients undergoing the intervention in the primary trial had adverse events, in comparison almost 10% patients in cohort 1 of the secondary trial experienced an adverse event, and more than 30% of those in cohort 2 of the secondary trial had adverse events. | Entailment | [
0,
1
] | [
0,
1,
8,
9
] | {'Clinical Trial ID': 'NCT00107276', 'Intervention': ['INTERVENTION 1: ', ' Cyclophosphamide and Capecitabine', ' cyclophosphamide orally days 1-14 and capecitabine orally days 15-21 for 8 cycles of 21 days each'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically or cytologically confirmed stage IV breas... | {'Clinical Trial ID': 'NCT00232505', 'Intervention': ['INTERVENTION 1: ', ' Cetuximab', ' Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II.', ' c... | 9a896e4a-ae6b-468c-a7c0-32c1514c0b48 |
Comparison | Intervention | NCT00356811 | NCT00296036 | The the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication topically. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00356811', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib Plus Paclitaxel', ' Participants received lapatinib 1500 mg orally OD with paclitaxel, administered as a 1-hour IV infusion at a dose of 80 mg/m^2 on Days 1, 8, and 15 (±2 days) of a 28-day treatment cycle for at least 6 months. Par... | {'Clinical Trial ID': 'NCT00296036', 'Intervention': ['INTERVENTION 1: ', ' Urea/Lactic Acid Cream', ' Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily.', 'INTERVENTION 2: ', ' Placebo Cream', ' Patients receive placebo cream applied to palms and soles twice daily.'], 'El... | 41eb4b9a-3b8f-4895-9aa3-cb43dbe27dd4 |
Comparison | Eligibility | NCT00290732 | NCT02748213 | Patients whose breast cancer has spread into both the skin and the chest wall are eligible for the secondary trial, but not the primary trial. | Entailment | [
2,
8
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00290732', 'Intervention': ['INTERVENTION 1: ', ' Intraductal Arm', ' Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.'], 'Eligibility': ['DISEASE CHARACTERIST... | {'Clinical Trial ID': 'NCT02748213', 'Intervention': ['INTERVENTION 1: ', ' Herceptin + Taxotere + Xeloda', ' Participants received triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal. Herceptin and Taxotere were given via IV infusion on Day 1 of each 21... | 0931065d-35e4-4f82-8ef6-ac6db900127a |
Single | Eligibility | NCT00853996 | Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model , and no Family history consistent with hereditary breast cancer, are eligible for the primary trial. | Contradiction | [
0,
1,
8
] | [] | {'Clinical Trial ID': 'NCT00853996', 'Intervention': ['INTERVENTION 1: ', ' Prevention (Acolbifene Hydrochloride)', ' Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.', ' acolbifene hydrochloride: Given orally'], 'Eligibility': ['Inclusion Criteria:', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 70912726-ba1b-47ef-9005-9584c8caf559 | |
Single | Results | NCT00493636 | Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [] | {'Clinical Trial ID': 'NCT00493636', 'Intervention': ['INTERVENTION 1: ', ' A (Sorafenib + Gemcitabine or Capecitabine)', ' Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Cape... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6743f85c-8318-49cc-acba-94aeb1f57130 | |
Comparison | Intervention | NCT00784849 | NCT02104895 | Accelerated partial Breast breast irradiation is used in some form for both cohorts of the secondary trial, but not at all in the primary trial. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00784849', 'Intervention': ['INTERVENTION 1: ', ' Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue', ' One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes'], 'Eligibility': ['Inclusion Criteria:', ' Stage 0,I, II breast cancer', ' Clinical nod... | {'Clinical Trial ID': 'NCT02104895', 'Intervention': ['INTERVENTION 1: ', ' Whole Breast Irradiation (WBI)', ' Conventional whole breast irradiation (WBI)', ' Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI)', 'INTERVENTION 2: ', ' Partial Breast Irradiation (APBI)', ' Accelerated partia... | ddffa26d-2581-477a-955c-ebf0c2ab0f97 |
Single | Adverse Events | NCT01201265 | 1 patient in the primary trial was affected by Sepsis. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT01201265', 'Intervention': ['INTERVENTION 1: ', ' All Participants', ' Participants received a combination therapy of bevacizumab 15 milligram per kilogram (mg/kg) intravenous every 3 weeks with carboplatin recommended dose (area under curve [AUC]= 2) along with gemcitabine 1000 mg/ metre sq... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f1a45b47-498d-45c8-b6d9-6c8f035da30b | |
Single | Adverse Events | NCT00179309 | There were no pain related adverse events observed in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [] | {'Clinical Trial ID': 'NCT00179309', 'Intervention': ['INTERVENTION 1: ', ' Arm I - PANVAC + Docetaxel', ' Patients receive vaccinia-carcinoembryonic antigen (CEA)- mucin-1 (MUC-1)- triad of costimulatory molecules (TRICOM) vaccine subcutaneously (SC) once and sargramostim, or granulocyte macrophage colony stimulatin... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a5272c37-0e32-42db-a44a-d17df7bd70ff | |
Single | Eligibility | NCT00201773 | Adele is an 85 year old woman with Stage IV histologically confirmed ER+ breast cancer with an ECOG of 0, she has a life expectancy below 6 months and a history of thrombotic events. She is eligible for the primary trial | Contradiction | [
0,
1,
2,
3,
4,
6
] | [] | {'Clinical Trial ID': 'NCT00201773', 'Intervention': ['INTERVENTION 1: ', ' Exemestane + Celecoxib', ' Exemestane + celecoxib (16 weeks) vs. Baseline', 'INTERVENTION 2: ', ' Exemestane', ' Exemestane (8 weeks) vs. Baseline'], 'Eligibility': ['Inclusion Criteria:', ' Must be female with histologically confirmed bre... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4c67a7b4-36fa-4c20-a15a-122609550973 | |
Single | Intervention | NCT00620373 | the primary trial tests two different dental imaging modalities, namely Mammography and gamma imaging. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00620373', 'Intervention': ['INTERVENTION 1: ', ' Mammography Only', ' For this reporting arm, the interpretation and analysis was done with mammography only.', 'INTERVENTION 2: ', ' Gamma Imaging', ' For this reporting arm, the interpretation and analysis was done with gamma imaging only.... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 120c6aa7-fcaa-4eaa-b520-6382968a6724 | |
Single | Results | NCT00050011 | the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD). | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | [] | {'Clinical Trial ID': 'NCT00050011', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid Upfront', ' Participants in the upfront arm received Zoledronic Acid 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence)or the end of study. Participants also received Letrozole 2.5 daily plus calcium ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645 | |
Comparison | Results | NCT00798135 | NCT01209195 | the primary trial and the secondary trial investigate different outcome measures for different interventions. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00798135', 'Intervention': ['INTERVENTION 1: ', ' Itraconazole', ' oral itraconazole 200mg a day until disease progression or unacceptable toxicities.'], 'Eligibility': ['Inclusion Criteria:', ' - Patients must have a pathologically confirmed diagnosis of invasive carcinoma of the breast. -... | {'Clinical Trial ID': 'NCT01209195', 'Intervention': ['INTERVENTION 1: ', ' Part 1: Dose Escalation: Cohort 1', ' MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV', 'INTERVENTION 2: ', ' Part 1: Dose Escalation: Cohort 2', ' MM-121 - 40 mg/kg loading dose followed by 20 m... | ac997ae1-7e48-48e2-af9e-f7e289622250 |
Single | Results | NCT02915744 | The difference in median Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month, the patient with the longest OS was in cohort 1. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT02915744', 'Intervention': ['INTERVENTION 1: ', ' NKTR-102', ' In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.', 'INTERVENTION 2: ', " Treatment of Physician's Choice (TPC)",... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 59328f44-6755-4dcb-b04c-4e0ce2ba3ac8 | |
Single | Results | NCT00399802 | The Lapatinib group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00399802', 'Intervention': ['INTERVENTION 1: ', ' Single IV Infusion of ZA 4 mg', ' Participants received a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks.', 'INTERVENTION 2: ', ' Once-daily Odanacatib 5 mg', ' Partic... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 441c0760-ca4a-4f1d-864e-a77395fd1f18 | |
Single | Results | NCT00723125 | 57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00723125', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1', ' Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fbe60029-8944-4e12-b4b2-3413037a10cc | |
Comparison | Intervention | NCT00278109 | NCT01881230 | Gemcitabine is not used in the primary trial, and used only in cohort 2 of the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00278109', 'Intervention': ['INTERVENTION 1: ', ' Experimental', ' cyclophosphamide: chemotherapy', ' doxorubicin hydrochloride: chemotherapy', ' adjuvant therapy: chemotherapy', ' radiation therapy: chemotherapy'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed a... | {'Clinical Trial ID': 'NCT01881230', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Nab-Paclitaxel + Gemcitabine', ' Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle... | fe1782aa-a871-4608-a7cb-8f83b7f76d8a |
Comparison | Intervention | NCT02364388 | NCT01425268 | There is no overlap in treatments used in the primary trial and the secondary trial. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT02364388', 'Intervention': ['INTERVENTION 1: ', ' MAESTRO', 'Baseline'], 'Eligibility': ['Inclusion Criteria', ' Female', ' 18 years of age or older', ' Have an undiagnosed suspicious finding which may include more than one solid or complex cystic suspicious mass, classified by CDU as BI-R... | {'Clinical Trial ID': 'NCT01425268', 'Intervention': ['INTERVENTION 1: ', ' AeroForm Tissue Expansion', ' AeroForm Tissue Expansion inflation with carbon dioxide by remote control', ' AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy... | a153ecbf-11ac-4c40-a3af-9dbb0e12c49b |
Single | Eligibility | NCT00405938 | Patients intracranial metastasis may be eligible for the primary trial. | Contradiction | [
9,
10
] | [] | {'Clinical Trial ID': 'NCT00405938', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab/Anastrozole', ' Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section be... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bcd48c1e-bfeb-4f1e-993f-cbbe4fadbf6e | |
Single | Results | NCT00263588 | The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26
] | [] | {'Clinical Trial ID': 'NCT00263588', 'Intervention': ['INTERVENTION 1: ', ' Cohort A', ' 750mg lapatinib administered orally twice daily. Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens, in total, for treatment of breast canc... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4dc22366-3ff3-41c8-aa4c-7342d7b7085d | |
Comparison | Adverse Events | NCT00645333 | NCT00006110 | the primary trial records several central nervous system related adverse events in its patients, whereas the secondary trial does not. | Contradiction | [
7,
8
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT00645333', 'Intervention': ['INTERVENTION 1: ', ' MK-0752 and Docetaxel', ' MK-0752 in escalating doses, orally days 1-3, followed by docetaxel 80 mg/m2 IV on day 8, and pegfilgrastim 6mg SQ day 9. Cycle repeated every 21 days.'], 'Eligibility': ['Inclusion Criteria:', ' Men or women with m... | {'Clinical Trial ID': 'NCT00006110', 'Intervention': ['INTERVENTION 1: ', ' Herceptin Regimen After AC', ' Patients in the adjuvant and neoadjuvant groups after receiving [AC-TP] Chemotherapy (doxorubicin & cyclophosphamide).', 'INTERVENTION 2: ', ' Herceptin Regimen After TP', ' Patients in the adjuvant and neoadj... | 196c2132-c735-4b79-bf03-3a830fcaf0fc |
Single | Adverse Events | NCT02924883 | In the primary trial, all cases of Enteritis, Vertigo and Cardiac failure occurred in cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [] | {'Clinical Trial ID': 'NCT02924883', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine + Placebo', ' Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or stu... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 72619b0a-57c2-465c-8428-72019b59f8ae | |
Single | Eligibility | NCT02732119 | Mark complained he had a racing heart twice in the last month and he is therefore excluded from the primary trial. | Contradiction | [
8,
14
] | [] | {'Clinical Trial ID': 'NCT02732119', 'Intervention': ['INTERVENTION 1: ', ' Cohort A', ' Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B', 'INTERVENTION 2: ', ' Cohort B', ' Ribociclib (300 mg daily), everolimus ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b8663fa7-585a-4cd9-afd2-89e8e1a58b82 | |
Comparison | Intervention | NCT02536794 | NCT00712985 | the primary trial and the secondary trial both administer treatments to their patients through IV. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT02536794', 'Intervention': ['INTERVENTION 1: ', ' Treatment (MEDI4736, Tremelimumab)', ' Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or una... | {'Clinical Trial ID': 'NCT00712985', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid 5 mg IV', ' Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose. Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx).'], 'Eligibility': ['Inclusion ... | 7c92d075-ba9d-45b5-9834-83b09d2753bc |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.